Lifeloc Technologies, Inc. filings document a Colorado operating company that reports as an SEC registrant and trades common stock under LCTC. Its Form 8-K reports furnish operating results, Regulation FD releases, and material-event disclosures tied to the company’s breath alcohol and drug detection device business.
The filing record also covers material financing agreements, debt terms, security interests, capital-structure matters, and the use of proceeds for continued SpinDetect™ product development. Proxy materials describe annual shareholder voting matters, director elections, auditor ratification, governance procedures, and common-stock ownership information.
Lifeloc Technologies, Inc. (LCTC) reported third-quarter 2026 revenue of $2,521,874, up 12% from $2,257,448 a year earlier, and a net loss of ($84,931), versus ($263,439). Diluted loss per share was ($0.03) versus ($0.10); gross margin was 43% versus 40%. For the first nine months, revenue was $7,260,643 versus $6,753,858, and net loss was ($371,974) versus ($949,764).
Lifeloc now expects a limited commercial launch of SpinDetect in Q4 2027, revised from its prior Q1 2027 expectation. Beta testing focused on delta-9-THC is planned with a prototype reader, with final component optimization underway under a signed agreement. The company is redirecting some resources to core alcohol products and expects upgrades to generate revenue to help fund SpinDetect; the revised timeline depends on that revenue and timely capital access. Nine-month net cash used in operating activities was $14,618, versus $578,437 in 2025.
Lifeloc Technologies, Inc. (LCTC) reported third-quarter revenue of $2,521,874, up 12% from a year earlier, while net loss narrowed to $84,931 from $263,439. Gross profit increased 20% to $1,090,082. For the first nine months, revenue rose 7.5% to $7,260,643 and net loss narrowed to $371,974 from $949,764.
Net cash used in operations for the nine months was $14,618, compared with $578,437 in 2025; cash and equivalents were $930,539 as of September 30, 2026. Management believes cash resources will fund operations for the next twelve months under its current plan, but says additional borrowing or capital may be required if the company cannot sustain profitability and cash-flow break-even.
The company says it will initiate beta testing of its SpinDetect™ oral-fluid analyzer focused on delta-9-THC, while redirecting some resources to core products. A $500,000 term loan from Chairman and CFO Vern D. Kornelsen is secured by substantially all company assets; its annual interest rate increased to 10.75% effective October 1, 2026.
Lifeloc Technologies, Inc. (LCTC) will participate in the virtual Lytham Partners Fall 2026 Investor Conference on September 29–30, 2026. Its webcast presentation is scheduled for September 29 at 2:45 p.m. ET, and one-on-one meetings with investors are available during the event by registration. The webcast will be available for replay following the event.
Management will provide background on Lifeloc’s breath alcohol testing business and discuss the status of its SpinDetect™ Analyzer project, described as new product development addressing market needs for rapid drug testing.
Lifeloc Technologies, Inc. reported stronger results for the quarter ended June 30, 2026. Net revenue was $2.445 million, up from $2.219 million a year earlier, and the net loss narrowed to $(134) thousand, or $(0.05) per diluted share, from $(394) thousand, or $(0.14) per share.
Gross margin improved to 45% from 42%, helped by price increases and favorable product mix, while research and development spending remained elevated at $560 thousand, largely for the SpinDetect™ analyzer. The company advanced SpinDetect development and is targeting a limited commercial launch of its oral-fluid drug analyzer in Q1 2027. During the quarter, Lifeloc also secured a $500,000 related-party term loan at 10.5% interest, secured by all company assets.
Lifeloc Technologies, Inc. reported higher sales but continued losses for the quarter and six months ended June 30, 2026, while advancing its SpinDetect™ drug-detection platform and increasing leverage. Quarterly revenues were $2.44 million, up 10% from 2025, driven mainly by stronger product sales despite lower royalties and discontinued rental income. Gross profit rose to $1.09 million, with gross margin improving to 45% from 42% on favorable product mix. Operating expenses declined across research and development, sales and marketing, and general and administrative costs, leading to a narrower quarterly net loss of $134,330 versus a loss of $393,639 a year earlier.
For the first half of 2026, revenues were $4.74 million, up 5%, and gross profit increased 13% to $2.08 million, with margins improving to 44%. The six‑month net loss shrank to $287,043 from $686,325 as spending was trimmed while maintaining substantial R&D on SpinDetect™, which is targeted for a limited commercial launch in early 2027. Cash and cash equivalents were $908,208, current liabilities $1.10 million, and total debt included a $1.09 million bank term loan, $797,855 in subordinated debentures, and a new $500,000 related‑party term loan at 10.5% interest secured by substantially all assets. Management believes existing resources under its current plan are sufficient for the next 12 months but acknowledges ongoing operating losses and the potential need for additional capital if sales growth or SpinDetect™ commercialization fall short.
Lifeloc Technologies director Michael Kornelsen increased his stake through a small open-market purchase. On June 16, 2026, he bought 100 shares of common stock at $2.50 per share. After this transaction, he directly owns 1,100 shares and has indirect beneficial ownership of 27,500 shares held by EDCO Partners LLLP.
Lifeloc Technologies CEO and President Wayne Willkomm reported an open-market purchase of common stock. He bought 1,300 shares of Lifeloc Technologies, Inc. at $2.50 per share. After this transaction, he directly owns 41,625 common shares.
The filing also shows an indirect holding of 23,477 common shares that are beneficially held by EDCO Partners LLLP on his behalf. This Form 4 primarily updates the market on his current direct and indirect ownership in Lifeloc Technologies (LCTC).
Lifeloc Technologies is advancing its SpinDetect™ Centrifugal Drug Analyzer from development into validation and early production. The company has completed production tooling for SpinDetect consumable disks, produced and tested first-article disks, made minor mold fixes, and commissioned a cleanroom with an automated reagent-dispensing robot.
Lifeloc plans a staged rollout, first targeting U.S. forensic and certain international markets, with U.S. workplace use following FDA clearance. The initial product will be a qualitative pass/fail delta-9-THC test, with quantitative and multi-drug panels to follow. The SpinDetect reader is expected to list at about $7,495 in the U.S.
Management highlights the system’s focus on measuring psychoactive delta-9-THC separately from inactive metabolites, which they view as a competitive differentiator for roadside and workplace testing. The company is also investing in its core breath alcohol L-series platform, including an OIML-variant of the LX9 device to broaden international reach and improve manufacturing costs.
Lifeloc Technologies, Inc. reported that Assure CPA, LLC resigned as its independent registered public accounting firm on June 3, 2026, after selling substantially all of its assets to Sadler, Gibb & Associates, LLC and ceasing public accounting operations. Assure’s audit reports for 2024 and 2025 contained no adverse opinions, and the company reports no disagreements or reportable events under Regulation S-K.
The company also summarized results of its June 3, 2026 annual meeting. Shareholders elected five directors, ratified the appointment of Assure CPA as independent auditor for fiscal 2026, approved an advisory say-on-pay vote on executive compensation, and adopted Amended and Restated Articles of Incorporation.
Lifeloc Technologies reported first quarter 2026 net revenue of $2.294 million and a net loss of $152,713, or $(0.06) per diluted share. Revenue grew about 1% from the prior year period, while the loss narrowed from $292,686 as gross margin improved to 43% from 40%.
Research and development remained significant at more than 18% of revenue, largely funding the SpinDetect™ Centrifugal Drug Analyzer. The company completed disk production tooling and received first article disks, described as the last enabling step before beta testing. Cash stood at $569,330 as of March 31, 2026, with total assets of $6.74 million.
In May 2026, Lifeloc closed a $500,000 loan from its Chairman and CFO at 10.5% interest, adjustable with prime, with interest-only payments in 2026 and a five-year repayment schedule and no prepayment penalty.